<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Summers, Jaye</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Lee, Virginia M.-Y.</style></author><author><style face="normal" font="default" size="100%">Scheffer, Ingrid E.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Applying Genetic Discoveries to the Treatment of PD and Epilepsy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-20 11:31:42</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">29-30</style></pages><abstract><style  face="normal" font="default" size="100%">Genetic breakthroughs have implications for both Parkinson disease and epilepsy. Evidence suggests that the monoclonal antibody Syn303 may represent a therapeutic advance in treating Parkinson disease. The discovery of genetic mutations and variants in families and others with epilepsy is providing groundbreaking insights regarding potential treatment options and surgical considerations.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>